Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL.
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.
Naval
N
Daver
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.
Marina
M
Konopleva
D017209:Apoptosis; D006801:Humans; D019253:Proto-Oncogene Proteins c-bcl-2; D051020:bcl-X Protein
D019253:Proto-Oncogene Proteins c-bcl-2; D051020:bcl-X Protein